Examples of using A third study in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Request for a third study group meeting REX/274- EU-Canada relations REX.
The efficacy and safety of a variation of the Zevalin therapeutic regimen employing a reduced dose of ibritumomab tiuxetan[90Y]was further defined in a third study enrolling a total of 30 patients who had mild thrombocytopenia platelet count 100,000 to 149,000 cells/mm3.
In a third study, 254 pigs infected with Trichuris suis were treated either with Panacur AquaSol or received no treatment.
The company also presented the results of a third study that compared the effects of MULTAQ and placebo on the heart rate in 174 patients who had had atrial fibrillation continuously for over six months.
A third study investigated the effectiveness of Kalydeco in patients with cystic fibrosis due to several mutations other than G551D.
Request for a third study group meeting REX/303- Decent work and sustainable development in the Mediterranean region REX.
A third study in 776 children compared the effects of M-M-RVAXPRO when given as injected into the muscle and when injected under the skin.
A third study compared Forxiga with a sulphonylurea(glipizide), both taken in combination with metformin in 814 patients.
A third study involving 139 patients compared Instanyl with fentanyl as a‘transmucosal' tablet absorbed through the lining of the mouth.
A third study, using a vaccine with strain A/turkey/Turkey/1/05(H5N1)-like strain(NIBRG-23), has been carried out in 343 adults aged below and above 60 years.
A third study focused on the current programming in Uganda, and intended to show what a future joint programming framework could look like in a given country.
In a third study in adults aged 50-93 years, it was demonstrated that Prevenar 13 may be given concomitantly with the seasonal quadrivalent inactivated influenza vaccine QIV.
In addition, a third study is ongoing in 5,623 patients where previous treatment with another disease-modifying therapy had failed glatiramer acetate, beta-interferon or fingolimod.
A third study examined the use of Privigen for immunomodulation in 28 patients with CIDP who were given Privigen every three weeks over a period of 24 weeks.
A third study, which involved 900 adults aged 18 to 49, compared the immune response to Prevenar 13 with the response in adults aged 60 to 64.
A third study in previously untreated patients compared the effects of giving peginterferon alfa and ribavirin for different lengths of time(either six months or one year) together with three months of Incivo treatment.
In a third study in patients with cancer of the head and neck including mouth cancer, Lymphoseek was used to detect sentinel lymph nodes before patients had their lymph nodes removed surgically.
A third study, D9902A, similar in design to study D9901, was terminated prior to completion of planned accrual based on the time to disease progression results in study D9901.
A third study studied the effects of Ultibro Breezhaler on the rate of exacerbations(flare-ups) patients experienced during 64 weeks of treatment when compared with treatment with glycopyrronium or tiotropium other treatments for COPD.
A third study, in 578 patients whose disease had not responded or had come back after previous treatment, compared adding Imbruvica or placebo(a dummy treatment) to the cancer medicines bendamustine and rituximab.
In a third study conducted in diabetic rats, administration of another human insulin with a formulation similar to Insuman via a catheter fixed to the liver capsule showed that intraperitoneal administration of high local insulin concentration at the liver capsule may induce reversible focal hepatic steatosis.
A third study(study 3) primarily evaluated the safety of Xolair in patients with CSU who remained symptomatic despite treatment with H1 antihistamines at up to four times the approved dose and H2 antihistamine and/or LTRA treatment.
Eighty antiretroviral naïve patients were entered into a third published study.
In a third main study in 846 newly diagnosed patients with chronic phase CML, Tasigna, either as 300 mg twice a day or as 400 mg twice a day, was compared with imatinib.
The third study had similar results.
In the third study, 15% 25 out of.
The third study compared Hycamtin given as an infusion and as capsules.
The third study did not compare Evra with any other medicine.
The third study involved 59 children aged two to 12 years.
The third study looked at the use of the medicine over three weeks.